(KFF)3K-L bacterial penetration peptide
Sequence: (KFF)3K-L
| Experiment Id | EXP002502 |
|---|---|
| Paper | A Novel Peptide Nucleic Acid against the Cytidine Monophosphate Kinase of S. aureus Inhibits Staphyl |
| Peptide | (KFF)3K-L bacterial penetration peptide |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 500 nmol per mouse in vivo |
| Rna Concentration | |
| Mixing Ratio | Peptide-PNA conjugate; no separate mixing ratio |
| Formulation Format | Peptide-conjugated PNA (P-PNA) |
| Formulation Components | (KFF)3K-L peptide covalently conjugated to ASP-cmk1 PNA oligomer |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | murine intraperitoneal S. aureus infection model |
| Cell Lines Or Primary Cells | |
| Animal Model | C57BL/6J mice challenged intraperitoneally with S. aureus ATCC 29740 |
| Administration Route | intraperitoneal injection after bacterial challenge |
| Output Type | bacterial burden reduction |
| Output Value | ASP-cmk1 significantly reduced bacterial loads in peritoneal fluid and kidneys at 20 h post-challenge by roughly 3–4 log scale magnitudes versus saline. |
| Output Units | |
| Output Notes | Functional in vivo anti-infective effect attributed to ASP-cmk1 P-PNA; no separate in vivo uptake assay was reported in the main paper. |
| Toxicity Notes | Intravenous ASP-cmk1 at 1,000 nmol did not induce behavioral changes or tissue damage in tested organs under evaluated conditions. |
| Curation Notes |